BMS' Opdivo/Yervoy OK'd; 1st U.S. Immuno-Oncology Combo
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb on Oct. 1 revealed it had gained the FDA's blessing under an accelerated approval to market Opdivo (nivolumab) plus Yervoy (ipilimumab) to treat patients with BRAF V600 wild-type unresectable or metastatic melanoma – the first immuno-oncology combination regimen approved in the U.S. in cancer.
You may also be interested in...
Another Opdivo Disappointment For BMS, This Time In Kidney Cancer
Bristol-Myers Squibb's Opdivo plus Yervoy in first-line RCC did not achieve statistical significance in terms of progression-free survival versus Sutent, but overall survival data aren't available yet.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.